Low-profile eye drop developer spells out the game plan that drew Brent Saunders to the board — and it involves going earlier than anti-VEGFs

When Brent Saunders took on the chairman role on OcuTerra Therapeutics’ board of directors a few months ago — his first biotech gig since selling …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Low-pro­file eye drop de­vel­op­er spells out the game plan that drew Brent Saun­ders to the board — and it in­volves go­ing ear­li­er than an­ti-VEG­Fs